The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지

Management of Complicated Gout

통풍의 합병증 치료

  • Jung, Young-Ok (Division of Rheumatology, Department of Internal Medicine, Hallym University College of Medicine, Kangnam Sacred Heart Hospital)
  • 정영옥 (한림대학교 의과대학 내과학교실, 강남성심병원 류마티스내과)
  • Published : 2011.03.01
⟨ Previous Next ⟩

Abstract

Chronic tophaceous gout results from long-term uncontrolled hyperuricemia with accumulation of urate crystals in joints, soft tissues, tendon sheaths and bony prominence. Urate-lowering agents should be administered to reduce serum uric acid level to less than 5 mg/dL for tophi reabsorption. Surgical indications include restoration of joint and tendon dysfunction, nerve decompression, debridement of septic joints, pain relief and cosmesis. Gout patients are at greater risk of forming uric acid stones. The renal tubular abnormality related to gout and metabolic syndrome leads to excretion of acidic urine, which favors formation of the relatively insoluble uric acid than more soluble urate. The corner stone of treatment of uric acid stone is urine alkalinization. Lowering serum uric acid with allopurinol and increasing urine volume are also important. Allopurinol is poorly tolerated and ineffective or contraindicated in some patients. Benzbromarone, a uricosuric agent is a useful alternative but possible hepatotoxicity should be monitored. Desensitization of allopurinol can be attempted to patients with mild cutaneous hypersensitivity. For gout patients with chronic renal failure, allopurinol dose need to be adjusted and nonsteroidal anti-inflammatory drugs and colchicine may be contraindicated.

Keywords

References

  1. Rott KT, Agudelo CA. Gout. JAMA 2003;289:2857-2860. https://doi.org/10.1001/jama.289.21.2857
  2. Moore JR, Weiland AJ. Gouty tenosynovitis in the hand. J Hand Surg Am 1985;10:291-295.
  3. Kumar S, Ng J, Gow P. Benzbromarone therapy in management of refractory gout. N Z Med J 2005;118:U1528.
  4. Wortmann RL. Recent advances in the management of gout and hyperuricemia. Curr Opin Rheumatol 2005;17:319-324. https://doi.org/10.1097/01.bor.0000162060.25895.a5
  5. Emmerson BT. The management of gout. N Engl J Med 1996; 334:445-451. https://doi.org/10.1056/NEJM199602153340707
  6. Fitzgerald BT, Setty A, Mudgal CS. Gout affecting the hand and wrist. J Am Acad Orthop Surg 2007;15:625-635.
  7. Kumar S, Gow P. A survey of indications, results and complications of surgery for tophaceous gout. N Z Med J 2002;115:U109.
  8. Yu TF, Gutman AB. Principles of current management of primary gout. Am J Med Sci 1967;254:893-907. https://doi.org/10.1097/00000441-196712000-00019
  9. Terkeltaub R, Bushinsky DA, Becker MA. Recent developments in our understanding of the renal basis of hyperuricemia and the development of novel antihyperuricemic therapeutics. Arthritis Res Ther 2006;8(Suppl 1):S4. https://doi.org/10.1186/ar1909
  10. Liebman SE, Taylor JG, Bushinsky DA. Uric acid nephrolithiasis. Curr Rheumatol Rep 2007;9:251-257. https://doi.org/10.1007/s11926-007-0040-z
  11. Daudon M, Traxer O, Conort P, Lacour B, Jungers P. Type 2 diabetes increases the risk for uric acid stones. J Am Soc Nephrol 2006;17:2026-2033. https://doi.org/10.1681/ASN.2006030262
  12. Sakhaee K, Adams-Huet B, Moe OW, Pak CY. Pathophysiologic basis for normouricosuric uric acid nephrolithiasis. Kidney Int 2002;62:971-979. https://doi.org/10.1046/j.1523-1755.2002.00508.x
  13. Bardin T. Current management of gout in patients unresponsive or allergic to allopurinol. Joint Bone Spine 2004;71:481-485. https://doi.org/10.1016/j.jbspin.2004.07.006
  14. Bardin T. Fenofibrate and losartan. Ann Rheum Dis 2003;62: 497-498. https://doi.org/10.1136/ard.62.6.497
  15. Feher MD, Hepburn AL, Hogarth MB, Ball SG, Kaye SA. Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout. Rheumatology (Oxford) 2003;42:321-325. https://doi.org/10.1093/rheumatology/keg103
  16. Hepburn AL, Kaye SA, Feher MD. Long-term remission from gout associated with fenofibrate therapy. Clin Rheumatol 2003; 22:73-76. https://doi.org/10.1007/s10067-002-0658-1
  17. Arai M, Yokosuka O, Fujiwara K, et al. Fulminant hepatic failure associated with benzbromarone treatment: a case report. J Gastroenterol Hepatol 2002;17:625-626. https://doi.org/10.1046/j.1440-1746.2002.02692.x
  18. Perez-Ruiz F, Calabozo M, Fernandez-Lopez MJ, et al. Treatment of chronic gout in patients with renal function impairment: an open, randomized, actively controlled study. J Clin Rheumatol 1999;5:49-55. https://doi.org/10.1097/00124743-199904000-00003
  19. Masbernard A, Giudicelli CP. Ten years' experience with benzbromarone in the management of gout and hyperuricaemia. S Afr Med J 1981;59:701-706.
  20. Fam AG, Lewtas J, Stein J, Paton TW. Desensitization to allopurinol in patients with gout and cutaneous reactions. Am J Med 1992;93:299-302. https://doi.org/10.1016/0002-9343(92)90236-5
  21. Fam AG, Dunne SM, Iazzetta J, Paton TW. Efficacy and safety of desensitization to allopurinol following cutaneous reactions. Arthritis Rheum 2001;44:231-238. https://doi.org/10.1002/1529-0131(200101)44:1<231::AID-ANR30>3.0.CO;2-7
  22. Avram Z, Krishnan E. Hyperuricaemia--where nephrology meets rheumatology. Rheumatology (Oxford) 2008;47:960-964. https://doi.org/10.1093/rheumatology/ken070
  23. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984;76:47-56.
  24. Vazquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001;60:981-983. https://doi.org/10.1136/ard.60.10.981
  25. Dalbeth N, Kumar S, Stamp L, Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006;33:1646-1650.
  26. Whelton A, Hamilton CW. Nonsteroidal anti-inflammatory drugs: effects on kidney function. J Clin Pharmacol 1991;31:588-598. https://doi.org/10.1002/j.1552-4604.1991.tb03743.x
  27. St Peter WL, Clark JL, Levos OM. Drug therapy in haemodialysis patients: special considerations in the elderly. Drugs Aging 1998;12:441-459. https://doi.org/10.2165/00002512-199812060-00003
  28. Wallace SL, Singer JZ, Duncan GJ, Wigley FM, Kuncl RW. Renal function predicts colchicine toxicity: guidelines for the prophylactic use of colchicine in gout. J Rheumatol 1991;18:264-269.